PCM
NAGE

Prelude Capital Management’s Niagen Bioscience NAGE Stock Holding History

Prelude Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,474
Closed -$82.1K – 1597
2024
Q4 		$82.1K Buy
+15,474
New +$84.7K 0.01% 1113

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's NAGE Position: Q1 2025 in Review

Prelude Capital Management sold out of Niagen Bioscience (NAGE) in Q1 2025, closing a stake of 15,474 shares — an estimated $82.1K sold.

Prelude Capital Management first reported a position in NAGE in Q4 2024 and held it in 1 quarter. The position peaked at $82.1K in Q4 2024. 139 funds tracked by Wall St. Rank hold NAGE as of Q1 2025.

  • Prelude Capital Management reported no remaining Niagen Bioscience position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 15,474 Niagen Bioscience shares in Q1 2025, an estimated $82.1K.
  • Prelude Capital Management first reported a position in Niagen Bioscience in Q4 2024 and held it in 1 quarter.
  • Prelude Capital Management's Niagen Bioscience position peaked at $82.1K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.